Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma

• Status: Recruiting
• Trial end date: 2024-11-30
• Target enrollment: 0
• Participant gender: All

Summary

A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genmab
• Collaborator: AbbVie
• Treatments: Bendamustine Hydrochloride; Carboplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Gemcitabine; Lenalidomide; Oxaliplatin; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria

1. Subject must sign an ICF

2. At least 18 years of age

3. Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on CT or MRI

4. ECOG PS score of 0, 1 or 2

5. Acceptable organ function at screening

6. CD20-positive NHL at most recent representative tumor biopsy

7. If of childbearing potential subject must practicing a highly effective method of birth control

8. A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control

Arm 1:

• Newly Diagnosed Documented DLBCL

• DLBCL, NOS

• "double-hit" or "triple-hit" DLBCL

• FL Grade 3B

Arm 2: R/R FL

Arm 3: Newly diagnosed, previously untreated FL grade 1-3A

Arm 4:

• Documented DLBCL and eligible for HDT-ASCT

• DLBCL, NOS

• "double-hit" or "triple-hit" DLBCL

• FL Grade 3B

Arm 5:

• Relapsed Documented DLBCL and ineligible for HDT-ASCT

• DLBCL, NOS

• "double-hit" or "triple-hit" DLBCL

• FL Grade 3B

Arm 6: Newly diagnosed, previously untreated FL grade 1-3A

Arm 7:

• FL Grade 1-3A

• If PR or CR per Lugano criteria following first-line or second-line treatment with SOC regimen, and last dose of SOC within 6 months prior to enrollment.

Exclusion Criteria

1. Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first dose of epcoritamab

2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.

3. Treatment with CAR-T therapy within 30 days prior to first dose of epcoritamab

4. Clinically significant cardiovascular disease

5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results

6. CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT scan of the brain and, if clinically indicated, by lumbar puncture

7. Active positive tests for hepatitis B virus or hepatitis C virus indicating acute or chronic infection

8. Known history of seropositivity of human immunodeficiency virus (HIV)

9. Suspected active or latent tuberculosis

10. Neuropathy > grade 1

11. Receiving immunostimulatory agent

12. Prior allogeneic HSCT